Pfizer

Pfizer faced the challenge of accelerating drug development and manufacturing at global scale, with traditional vaccine and drug development timelines spanning 8-10 years. Managing vast scientific data across global R&D and manufacturing operations created bottlenecks in research velocity and supply chain efficiency.

Pfizer centralized its data, migrated to AWS cloud infrastructure, and built a Scientific Data Cloud to enable faster research and drug development. The company implemented generative AI solutions using Amazon SageMaker and Amazon Bedrock to accelerate research workflows and improve manufacturing efficiency across its operations.

Pfizer treated 1.3 billion patients globally in 2022. The AWS partnership enabled Pfizer to develop and distribute the COVID-19 vaccine in just 269 days, compared to the typical 8-10 year development timeline. Cloud migration and AI adoption also saved millions annually in operational costs.

• Centralizing scientific data in a cloud-native architecture is a prerequisite for meaningful AI-driven research acceleration.
• Generative AI applied to R&D and manufacturing can compress development timelines by orders of magnitude when paired with proper data infrastructure.
• Strategic cloud partnerships can become a critical enabler during time-sensitive public health emergencies.